Table 3 Summary of overall survival – multivariable assessments.

From: Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation

Measure

Overall survival

Hazard ratio (95% CI)

p-value

CD34+ (×106 cells/kg)

 >2.5 vs. ≤2.5

0.59 (0.44, 0.79)

<0.001

Age at auto-HCT

 Continuous

1.03 (1.02, 1.03)

<0.001

Year of auto-HCT

 ≥2010 vs. <2010

1.00 (0.83, 1.20)

0.99

R-ISS

 II vs. I

1.27 (1.00, 1.60)

0.046

 III vs. I

2.08 (1.46, 2.97)

<0.001

 Unknown vs. I

2.16 (1.71, 2.73)

<0.001

Light chain type

 Lambda vs. Kappa

1.27 (1.10, 1.47)

<0.001

 Biclonal vs. Kappa

0.91 (0.37, 2.19)

0.83

 Unknown vs. Kappa

1.84 (0.59, 5.77)

0.30

Cytogenetic risk

 High vs. Standard

2.15 (1.78, 2.60)

<0.001

 Unknown vs. Standard

1.33 (1.04, 1.69)

0.024

LDH

 >ULN vs. Normal

1.25 (0.98, 1.60)

0.07

 Unknown vs. Normal

0.97 (0.81, 1.14)

0.68

Creatinine

 >2 vs. ≤2

1.14 (0.93, 1.38)

0.20

 Unknown vs. ≤2

0.80 (0.60, 1.07)

0.14

HCT-CI

 >3 vs. ≤3

1.41 (1.20, 1.65)

<0.001

 Unknown vs. ≤3

2.14 (0.30, 15.32)

0.45

Induction treatment

 KRD vs. Other

0.79 (0.55, 1.12)

0.19

MRD negative ≥ VGPR prior to auto-HCT

 Yes vs. No

1.08 (0.86, 1.36)

0.51

Best post-transplant responsea

 CR vs. non-CR

0.50 (0.43, 0.59)

<0.001

Maintenance therapya

 Yes vs. No

0.69 (0.59, 0.81)

<0.001

  1. auto-HCT autologous hematopoietic stem cell transplant, CI confidence interval, CR complete response, HCT-CI hematopoietic cell transplantation-specific comorbidity index, KRD carfilzomib, lenalidomide, dexamethasone, LDH lactate dehydrogenase, MRD minimal residual disease, R-ISS Revised International Staging Systems, ULN upper limit of normal, VGPR very good partial response.
  2. aIncluded in the model as a time-dependent covariate.
Back to article page